S2752 New Onset Inflammatory Bowel Disease Due to Anti-IL-17 Therapy With a Unique Twist

Abstract

Introduction: Both psoriasis and inflammatory bowel disease (IBD) are driven by inappropriate immune responses. Antibody therapy to the pro-inflammatory cytokine interlukin-17 (IL-17) has been associated with de-novo IBD. We describe two cases of new onset IBD in patients started on anti-IL-17 antibodies ixekizumab and secukinumab, both with unique clinical courses. Case Description/Methods: Patient 1: A 47-year-old woman with hypertension, type 2 diabetes mellitus, and psoriasis presented with 2 weeks of abdominal cramping and rectal bleeding. She had been stable on brodalumab but switched to ixekizumab two months prior to presentation. She denied a family history of IBD. Her labs were notable for mild leukocytosis, thrombocytosis, and elevated CRP. CT showed evidence of descending colitis. Colonoscopy revealed multifocal colitis, with biopsies suggesting IBD or drug-induced colitis. She was started on ustekinumab for Crohn's disease which resolved her GI symptoms. Repeat colonoscopy one year later confirmed endoscopic and histologic remission. Patient 2: A 36-year-old woman with pre-diabetes and psoriasis presented with watery diarrhea, abdominal cramping and stool discharge per vagina one week after switching from adalimumab to secukinumab. She reported a family history of Crohn’s disease in her mother. Her labs were notable for leukocytosis, thrombocytosis, and elevated CRP. CT revealed left sided colitis and MR showed a rectovaginal fistula. Colonoscopy revealed ileo-pancolitis and biopsies were consistent with IBD or drug-induced colitis. Secukinumab was discontinued. One week after discharge, the patient reported cessation of stool discharge per vagina and improvement in diarrhea and abdominal pain. Discussion: These case reports add to the literature that describes a relationship between IL-17 antagonism and IBD. Patient 1 is unique in that she was exposed to two different IL-17 antibodies prior to her diagnosis of IBD and she represents the first reported case of ustekinumab rescue of ixekizumab-induced IBD. Patient 2 is the only case of IL-17-induced IBD with a rectovaginal fistula described in the literature. Although recent meta-analyses do not show a statistically significant relationship between anti-IL-17 therapy and de-novo IBD, further study is warranted. Providers should avoid anti-IL-17 therapies for patients with a personal history of IBD and should monitor patients on these therapies closely for the development of IBD.